Antiviral medications, including those that treat hepatitis C and HIV/AIDS, cost the Medicaid program more money (before rebates) than any other group of outpatient prescription drugs for each year from 2014 to 2017, according to a new KFF analysis. Th…
Although the outpatient drug benefit accounts for only 6% of total Medicaid spending, drug spending has increased by double digits in recent years, and is expected to grow faster than most other Medicaid services in the next 10 years. This issue brief …
A new issue brief looks at long-term trends in employer-based health insurance coverage, and finds that although the share of nonelderly Americans with employer-based health insurance has risen modestly in recent years, the long-term trend still shows …
Despite Medicare’s protections, Part D enrollees with serious health conditions can face thousands of dollars in annual out-of-pocket costs for expensive specialty drugs, a new KFF anaylsis finds. The analysis draws on data from Medicare’s Plan Finder …
Medicare Part D has helped to make prescription drugs more affordable for people with Medicare, yet many beneficiaries continue to face high out-of-pocket costs for their medications. Specialty tier drugs are a particular concern for Part D enrollees i…
This slideshow examines how cost and insurance affects people’s access to care, including decisions to forgo or delay needed care and access to a usual source of care. The data finds those without health insurance or in poor health are more likely to …
This slideshow explores the variation in health spending across the population through an analysis of the 2012 Medical Expenditure Panel Survey data. The analysis shows that the 1% of the population with the highest spending accounted for almost one qu…
This conference report summarizes discussions at a March 2018 conference in Washington with 30 leaders from the health care community to launch Initiative 18/11, a partnership between the Society of Actuaries and KFF to address the rising cost of healt…
This conference report summarizes discussions at a March 2018 conference in Washington with 30 leaders from the health care community to launch Initiative 18/11, a partnership between the Society of Actuaries and KFF to address the rising cost of healt…
In this Axios column, Drew Altman wades in to the Medicare for All discussion focusing on the pros and cons of a critical but under-discussed feature of the proposals-they have no cost sharing.
